Brainstorm Cell Therapeutics (BCLI)
(Real Time Quote from BATS)
$0.24 USD
0.00 (0.00%)
Updated Sep 20, 2024 01:44 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
BCLI 0.24 0.00(0.00%)
Will BCLI be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BCLI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BCLI
Biotech Stock Roundup: MACK Up on Study Data, MRNA Offers Vaccine Update & More
BCLI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BCLI
BrainStorm files to sell 16.67M shares of common stock for holders
Brainstorm Cell Therapeutics Enacts Key Corporate Changes
BrainStorm files $172.56M mixed securities shelf
Brainstorm Cell Therapeutics Inc (BCLI) Q2 2024 Earnings Call Transcript Highlights: ...
Buy Rating Affirmed for Brainstorm Cell Therapeutics Amid Strategic Advances and Robust Financials